132 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
1 study for both indications.
We expect topline data from the Phase 1 study with CDI-988 in 2024.
2023 Financial Results
Research and development (R … expenses:
Research and development
General and administrative
Legal settlement
Impairments
Total operating expenses
Loss from operations
Other (expense
8-K
COCP
Cocrystal Pharma Inc
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
the compounds to meet a specific aspect of Merck’s program.
Under the terms of the Agreement, Merck funded research and development of influenza A/B
8-K
EX-99.1
ssrxbeo3fe4md747k7r
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
qdcq f5hihwnhqctn43
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K
EX-99.1
xdxjqv6x z1
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
qap9jew
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
ikydc8
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am